Tibet Aim Pharm.Inc. (China)

Tibet Aim Pharm.Inc., also known as Yi Ming Medicine, is a comprehensive pharmaceutical company that was established in December 2003. The company is headquartered in the national economic and technological development zone in Lhasa, Tibet Autonomous Region. It has subsidiaries including Beijing Yi Ming Kang Yuan Medicine Technology Co., Ltd., Chengdu Yi Ming Kang Yuan Medicine Technology Co., Ltd., Lhasa Yi Ming Kang Yuan Medicine Technology Co., Ltd., Beijing Yi Ming Hai Zhong Investment Management Co., Ltd., and Sichuan Vio Pharmaceutical Co., Ltd. The company's planting base is located in Nyingchi, Tibet, and its production bases are in Lhasa and Pengzhou, Sichuan, with a nationwide marketing network. The company has focused on the development and research of core products in the treatment of chronic diseases such as diabetes, cardiovascular diseases, and gynecology and obstetrics. Its core products, including Yi Ming® Aotianping® Miglitol Tablets, Xin Tong® Guanlupi Injection, Yi Mei Fen® Na Mifen Hydrochloride Injection, Yi Ming® Xin Nuoshu® Cabergoline Injection, Yi Ming® Mei Xiaodan® Hongjin Xiaojie Tablets, and Wei Pu Fen® Acemetacin Enteric-coated Tablets, have been included in the national medical insurance catalog. The company also produces a wide range of generic drugs, including antibiotics, antiallergic drugs, and digestive system drugs. The company adheres to the corporate philosophy of "simplicity, pragmatism, innovation, and win-win." It focuses on research and development as the driving force and results-oriented management philosophy. It holds multiple domestic first generic drug patents, award-winning patents, new drug certificates, and drug production registration approvals. The company has been honored with titles such as "Science and Technology Small and Medium-sized Enterprise in Tibet Autonomous Region," "National High-tech Enterprise," "National Science and Technology Incubation Enterprise," "Tibet National Science and Technology Incubation Enterprise," "Director Unit of China Cardiovascular and Cerebrovascular Disease Diagnosis and Treatment Industry Technology Innovation Strategic Alliance (Tibet)," and "China Patent Excellence Award." Thanks to the unique biological resources and national policy advantages of Tibet, the company has experienced rapid development and was officially listed on the Shenzhen Stock Exchange on December 9, 2016. In the future, the company will continue to utilize its core product advantages, analyze and grasp market challenges and opportunities comprehensively, adapt to the new pharmaceutical system reform and development model, and systematically build a high-quality human resources management system, financial management system, and operational development system. With the opportunity to enter the capital market, the company's vision is to "help patients overcome diseases and always maintain people's health." It aims to become a leading high-end generic drug company in the field of chronic diseases in China, with high-quality, cost-effective drugs that have significant clinical value. The company shoulders the social responsibility that Chinese pharmaceutical companies should have, pursues excellence, and strives to be at the forefront of the industry.